Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.

PURPOSE Standard therapies for locally advanced prostate cancer have resulted in suboptimal disease control rates. A Phase I/II trial was designed for patients with positive seminal vesicle biopsies, prostate-specific antigen (PSA) >15 ng/ml, Gleason score > or =8 or clinical classification T2c-T3 to improve local control and to test the tolerance of the prostate to high-dose radiation by using neoadjuvant hormonal therapy, 103Pd brachytherapy, and conformal three-dimensional external beam radiation therapy (EBRT). This article outlines treatment-related morbidity and PSA response to this regimen and analyzes the effect of escalating doses of brachytherapy. METHODS AND MATERIALS Forth-three patients with T1c-T3 prostate cancer were enrolled in a Phase I/II trial from March 1994 through September 1997. Follow-up ranged from 12 to 64 months (median, 32 months). Pretreatment PSA ranged from 2.1 to 202 ng/ml (median, 16 ng/ml). Seventy-seven percent (33 of 43) of patients had high-grade tumors (score > or =7). Seventy-four percent (32 of 43) had stage > or =T2c. A total of 21 (49%) patients had positive seminal vesicle biopsies. Treatment consisted of hormonal therapy for 3 months with leuprolide and flutamide followed by a 103Pd implant and, 2 months later, 59.4 Gy of three-dimensional EBRT. Hormonal therapy was continued for 9 months. The planned 103Pd dose was escalated from 57 Gy (13 patients) to 77 Gy (13 patients) to 86 Gy (17 patients). RESULTS The actuarial freedom from PSA failure (PSA>0.5 ng/ml) at 4 years was 74%. There were no significant differences found when analyzing patients by presenting PSA or seminal vesicle status. There was a trend toward improved outcome with higher doses delivered to the prostate via the implant. Patients receiving doses > or =65 Gy (31 patients) had a freedom from PSA failure rate at 4 years of 89.5%, compared with 52.5% for those receiving doses <65 Gy (10 patients; p=0.08). The last PSA values for those patients free from PSA failure were < or =0.1 ng/ml in 25 (69%), >0.1-0.2 ng/ml in 5 (14%), and >0.2-0.5 ng/ml in 6 (17%). The actuarial freedom from developing Grade 2 proctitis was 75% at 4 years. There was a trend toward increased proctitis with increasing prostate implant doses. Patients with doses < or =70 Gy (n=12) had a 92% freedom from Grade 2 proctitis compared with 67.5% for those with doses delivered to 90% of the gland from a dose-volume histogram of >70 Gy (n=29) (p=0.15). There were no cases of Grade 3 or 4 proctitis. The 3-year actuarial preservation of sexual potency rate was 43%. CONCLUSIONS The preliminary results from this regimen show an improvement in PSA control for this group of locally advanced prostate cancer patients over more standard therapies. To maximize control while minimizing toxicity, doses of 65-70 Gy of 103Pd should be used when 59.4 Gy of three-dimensional EBRT is delivered. Longer follow-up will be needed to further substantiate these findings.

[1]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[2]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[3]  W. Catalona,et al.  Nerve-Sparing Radical Prostatectomy , 1989 .

[4]  A. Zietman,et al.  Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. , 1994, Urology.

[5]  G. Zagars Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. , 1992, International journal of radiation oncology, biology, physics.

[6]  D. Kuban,et al.  Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[7]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[8]  M. Kattan,et al.  Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. , 1997, Urology.

[9]  I. Thompson,et al.  Salvage radical prostatectomy for adenocarcinoma of the prostate , 1988, Cancer.

[10]  M. Zelefsky,et al.  Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma , 1999, Cancer.

[11]  W. Caldwell,et al.  Biopsy-proved tumor following definitive irradiation for resectable carcinoma of the prostate. , 1972, The Journal of urology.

[12]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[13]  J. Mcaninch,et al.  Latent residual tumor following external radiotherapy for prostate adenocarcinoma. , 1978, The Journal of urology.

[14]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[15]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[16]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[17]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[18]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[19]  A. K. Levinson,et al.  The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. , 1997, Urology.

[20]  A. Zietman,et al.  The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. , 1997, The cancer journal from Scientific American.

[21]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[22]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[23]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[24]  H. Ragde,et al.  Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma , 1999, Cancer.

[25]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[26]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[27]  Julie Dawson,et al.  Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants , 1994 .

[28]  G. Lederman,et al.  High dose combination radiotherapy for the treatment of localized prostate cancer. , 1998, The Journal of urology.

[29]  E. Jones,et al.  Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. , 1990, The Journal of urology.

[30]  P. Walsh Editorial: The Status of Radical Prostatectomy in the United States in 1993: Where do we go from here? , 1994 .

[31]  W. Catalona,et al.  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. , 1990, The Journal of urology.

[32]  P. Scardino,et al.  The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. , 1986, The Journal of urology.

[33]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[34]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[35]  A. Hanlon,et al.  Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Scardino,et al.  Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. , 1992, The Journal of urology.